Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Click Chemistry-Mediated Complementation Assay for RNA-Protein Interactions.

Sherman EJ, Lorenz DA, Garner AL.

ACS Comb Sci. 2019 Jun 7. doi: 10.1021/acscombsci.9b00071. [Epub ahead of print]


Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Sherman EJ, Dunn LA, Schöder H, Ho AL, Baxi SS, Ghossein RA, Haque SS, Sima C, Tuttle RM, Pfister DG.

Cancer. 2019 Jun 7. doi: 10.1002/cncr.32046. [Epub ahead of print]


Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.

Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG, Ho AL.

J Clin Oncol. 2019 Jun 20;37(18):1529-1537. doi: 10.1200/JCO.18.01859. Epub 2019 Apr 2.


Long-term quality of life in older patients with HPV-related oropharyngeal cancer.

Baxi SS, Cullen G, Xiao H, Atoria CL, Sherman EJ, Ho A, Lee NY, Elkin EB, Pfister DG.

Head Neck. 2018 Nov;40(11):2321-2328. doi: 10.1002/hed.25159. Epub 2018 Nov 13.


Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL.

J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478.


Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot.

Ma J, Lok BH, Zong J, Gutiontov SI, Cai X, Bell AC, Shcherba M, Xiao H, Sherman EJ, Tsai CJ, Riaz N, McBride SM, Cahlon O, Lee NY.

Int J Part Ther. 2018 Spring;4(4):10-19. doi: 10.14338/IJPT-18-00003.1.


Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.

Beckham TH, Romesser PB, Groen AH, Sabol C, Shaha AR, Sabra M, Brinkman T, Spielsinger D, McBride S, Tsai CJ, Riaz N, Tuttle RM, Fagin JA, Sherman EJ, Wong RJ, Lee NY.

Thyroid. 2018 Sep;28(9):1180-1189. doi: 10.1089/thy.2018.0214.


Targeting VEGF and EGFR: a combination worth re-exploring?

Tchekmedyian V, Sherman EJ.

Lancet Oncol. 2018 Aug;19(8):1007-1009. doi: 10.1016/S1470-2045(18)30377-2. Epub 2018 Jul 11. No abstract available.


Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery.

Katsoulakis E, Leeman JE, Lok BH, Shi W, Zhang Z, Tsai JC, McBride SM, Sherman EJ, Cohen M, Wong R, Ganly I, Lee NY, Riaz N.

Laryngoscope. 2018 Nov;128(11):2539-2545. doi: 10.1002/lary.27191. Epub 2018 Apr 10.


Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks.

Leeman JE, McBride SM, Spielsinger D, Sherman EJ, Wong R, Riaz N, Lee NY, Tsai CJ.

Int J Cancer. 2018 Jun 15;142(12):2485-2490. doi: 10.1002/ijc.31277. Epub 2018 Feb 10.


A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, Pfister C, Haque S, Katabi N, Ho AL, Pfister DG.

Ann Oncol. 2018 Jul 1;29(7):1606. doi: 10.1093/annonc/mdx801. No abstract available.


Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.

Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, Pfister DG.

Head Neck. 2018 Feb;40(2):233-241. doi: 10.1002/hed.24938. Epub 2017 Sep 30.


A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, Pfister C, Haque S, Katabi N, Ho AL, Pfister DG.

Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346.


Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.

Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 Dec 1;123(23):4583-4593. doi: 10.1002/cncr.30933. Epub 2017 Aug 17.


Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG.

Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29.


Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.

Leeman JE, Li JG, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle JO, Roman BR, Morris LGT, Dunn LA, Sherman EJ, Lee NY, Riaz N.

JAMA Oncol. 2017 Nov 1;3(11):1487-1494. doi: 10.1001/jamaoncol.2017.0973.


Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.


Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.

Zumsteg ZS, Kim S, David JM, Yoshida EJ, Tighiouart M, Shiao SL, Scher K, Mita A, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 May 1;123(9):1555-1565. doi: 10.1002/cncr.30508. Epub 2016 Dec 21.


The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.

Zumsteg ZS, Lok BH, Ho AS, Drill E, Zhang Z, Riaz N, Shiao SL, Ma J, McBride SM, Tsai CJ, Baxi SS, Sherman EJ, Lee NY.

Cancer. 2017 Apr 15;123(8):1345-1353. doi: 10.1002/cncr.30495. Epub 2016 Dec 16.


A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.

Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Haque S, Sima CS, Ni A, Antonescu CR, Katabi N, Pfister DG.

Ann Oncol. 2016 Oct;27(10):1902-8. doi: 10.1093/annonc/mdw287. Epub 2016 Aug 26.


Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ.

Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.


The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.

Morris LGT, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Dogan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL.

JAMA Oncol. 2017 Feb 1;3(2):244-255. doi: 10.1001/jamaoncol.2016.1790.


Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.

Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, Michael Tuttle R, Fagin JA, Klimstra DS, Katabi N, Ghossein RA.

Mod Pathol. 2016 Sep;29(9):985-95. doi: 10.1038/modpathol.2016.115. Epub 2016 Jun 10.


Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer.

Baxi SS, Salz T, Xiao H, Atoria CL, Ho A, Smith-Marrone S, Sherman EJ, Lee NY, Elkin EB, Pfister DG.

Cancers Head Neck. 2016 Jun 3;1:4. doi: 10.1186/s41199-016-0002-0. eCollection 2016.


Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.

Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY.

Radiother Oncol. 2016 Feb;118(2):286-92. doi: 10.1016/j.radonc.2015.12.008. Epub 2016 Feb 8.


Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers.

Lok BH, Jiang G, Gutiontov S, Lanning RM, Sridhara S, Sherman EJ, Tsai CJ, McBride SM, Riaz N, Lee NY.

Oral Oncol. 2015 Oct;51(10):957-62. doi: 10.1016/j.oraloncology.2015.07.011. Epub 2015 Aug 14.


Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience.

Scher ED, Romesser PB, Chen C, Ho F, Wuu Y, Sherman EJ, Fury MG, Wong RJ, McBride S, Lee NY, Riaz N.

Oral Oncol. 2015 Jul;51(7):709-15. doi: 10.1016/j.oraloncology.2015.04.007. Epub 2015 May 7.


Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.

Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, Gewanter R, Gelblum D, Haque S, Schoder H, Shah JP, Katabi N, Kurtzman R, Lipson B, Cox L, Lee NY, Pfister DG.

Head Neck. 2016 Apr;38 Suppl 1:E566-70. doi: 10.1002/hed.24041. Epub 2015 Jul 6.


Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.

O'Neill CB, Baxi SS, Atoria CL, O'Neill JP, Henman MC, Sherman EJ, Lee NY, Pfister DG, Elkin EB.

Cancer. 2015 Jun 15;121(12):2083-9. doi: 10.1002/cncr.29262. Epub 2015 Feb 27.


Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab.

Baxi SS, O'Neill C, Sherman EJ, Atoria CL, Lee NY, Pfister DG, Elkin EB.

Head Neck. 2016 Apr;38 Suppl 1:E165-71. doi: 10.1002/hed.23961. Epub 2015 Jun 26.


Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS.

J Clin Oncol. 2014 Sep 20;32(27):2940-50.


Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).

Shapiro LQ, Sherman EJ, Riaz N, Setton J, Koutcher L, Zhang Z, Shi W, Fury MG, Wolden SL, Pfister DG, Morris L, Lee N.

Oral Oncol. 2014 Oct;50(10):947-55. doi: 10.1016/j.oraloncology.2014.07.001. Epub 2014 Aug 11.


A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Riaz N, Hong JC, Sherman EJ, Morris L, Fury M, Ganly I, Wang TJ, Shi W, Wolden SL, Jackson A, Wong RJ, Zhang Z, Rao SD, Lee NY.

Radiother Oncol. 2014 Jun;111(3):382-7. doi: 10.1016/j.radonc.2014.06.003. Epub 2014 Jun 30.


External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.

Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY.

J Surg Oncol. 2014 Sep;110(4):375-82. doi: 10.1002/jso.23656. Epub 2014 Jun 24.


A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.

Ho AL, Lipson BL, Sherman EJ, Xiao H, Fury MG, Apollo A, Seetharamu N, Sima CS, Haque S, Lyo JK, Sales R, Cox L, Pfister DG.

Invest New Drugs. 2014 Jun;32(3):549-54. doi: 10.1007/s10637-014-0073-x. Epub 2014 Feb 25.


Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY, Pfister DG.

Ann Oncol. 2014 Mar;25(3):689-94. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3.


Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.


Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA.

Cancer Discov. 2013 May;3(5):520-33. doi: 10.1158/2159-8290.CD-12-0531. Epub 2013 Jan 29.


Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.


Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?

Riaz N, Sherman EJ, Fury M, Lee N.

J Clin Oncol. 2013 Jan 10;31(2):287-8. doi: 10.1200/JCO.2012.46.9049. Epub 2012 Dec 3. No abstract available.


Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.

Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, Pfister DG.

Thyroid. 2013 May;23(5):593-9. doi: 10.1089/thy.2012.0393.


Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know.

Baxi SS, Shuman AG, Corner GW, Shuk E, Sherman EJ, Elkin EB, Hay JL, Pfister DG.

Head Neck. 2013 Nov;35(11):1534-41. doi: 10.1002/hed.23182. Epub 2012 Nov 20.


Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy.

Romesser PB, Romanyshyn JC, Schupak KD, Setton J, Riaz N, Wolden SL, Gelblum DY, Sherman EJ, Kraus D, Lee NY.

Cancer. 2012 Dec 15;118(24):6072-8. doi: 10.1002/cncr.27633. Epub 2012 Jun 15.


Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer.

Baxi SS, Sherman EJ, Kelly KW, Brown KT, Dematteo RP, Pfister DG.

Thyroid. 2012 May;22(5):552-5. doi: 10.1089/thy.2011.0413. Epub 2012 Apr 17.


TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome.

Sherman EJ, Fisher SG, Kraus DH, Zelefsky MJ, Seshan VE, Singh B, Shaha AR, Shah JP, Wolf GT, Pfister DG.

Laryngoscope. 2012 May;122(5):1043-50. doi: 10.1002/lary.23220. Epub 2012 Feb 28.


Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.

Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY, Pfister DG.

Radiother Oncol. 2011 Dec;101(3):425-30. doi: 10.1016/j.radonc.2011.09.004. Epub 2011 Oct 6.


Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.

Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1851-7. doi: 10.1016/j.ijrobp.2011.03.029. Epub 2011 Jun 2.


Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.

Setton J, Caria N, Romanyshyn J, Koutcher L, Wolden SL, Zelefsky MJ, Rowan N, Sherman EJ, Fury MG, Pfister DG, Wong RJ, Shah JP, Kraus DH, Shi W, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):291-8. doi: 10.1016/j.ijrobp.2010.10.041. Epub 2010 Dec 16.


Supplemental Content

Loading ...
Support Center